(Q24193614)

21

0 references

Kristina Lindsley

10

0 references

Kay Dickersin

8

0 references

Roberto D'Amico

7

0 references

Christine Schmucker

19

0 references

Alessandro Mugelli

14

0 references

Ersilia Lucenteforte

2

0 references

Usha Chakravarthy

Usha Chakravarthy

6

0 references

Laurent Kodjikian

9

Laurent Kodjikian

0 references

Yoon K Loke

11

Yoon Loke

0 references

Vittorio Bertele

4

Vittorio Bertele

0 references

Koren Hyogene Kwag

3

Koren H Kwag

0 references

Annalisa Campomori

5

Annalisa Campomori

0 references

Maureen G Maguire

12

Maureen Maguire

0 references

Isabel Püntmann

16

Isabel Püntmann

0 references

Barnaby C Reeves

17

Barnaby Reeves

0 references

Manju L Subramanian

20

Manju L Subramanian

0 references

author name string

Daniel F Martin

13

0 references

Bernd Mühlbauer

15

0 references

Chris Rogers

Cochrane Database of Systematic Reviews

18

0 references

language of work or name

English

0 references

publication date

2014

0 references

published in

0 references

volume

9

0 references

issue

9

0 references

page(s)

CD011230

0 references

cites work

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

0 references

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Measuring inconsistency in meta-analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Incidence and management of bevacizumab-related toxicities in colorectal cancer

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Contradicted and initially stronger effects in highly cited clinical research

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Non-publication and delayed publication of randomized trials on vaccines: survey.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Prevalence, characteristics, and publication of discontinued randomized trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Cardiac issues of noncardiac drugs: the rising story of avastin in age-related macular degeneration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Vascular endothelial growth factor a in intraocular vascular disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

The estimated prevalence and incidence of late stage age related macular degeneration in the UK

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Reflections on meta-analyses involving trials stopped early for benefit: is there a problem and if so, what is it?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Bevacizumab increases risk for severe proteinuria in cancer patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Neovascular age-related macular degeneration: potential therapies.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Evaluation of networks of randomized trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Discrepancies between meta-analyses and subsequent large randomized, controlled trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4262120

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial

27 September 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011230.PUB2

Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011230.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011230.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011230.PUB2

GRADE guidelines 6. Rating the quality of evidence—imprecision

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011230.PUB2

Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011230.PUB2

Testing intravitreal toxicity of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011230.PUB2

Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011230.PUB2

Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011230.PUB2

Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?

21 January 2018

1 reference

12 December 2020

Age-related macular degeneration

1 reference

12 December 2020

Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study.

1 reference

12 December 2020

The impact of high-risk patients on the results of clinical trials

1 reference

12 December 2020